| Symbol
| CEACAM1
| contributors: mct/npt/pgu - updated : 09-11-2015
|
| HGNC name
| carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
|
| HGNC id
| 1814
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --low
|
| |
in colorectal carcinoma | | tumoral
|
|
| --over
|
|
in some tumors such as non-small cell lung cancer  | | tumoral
|
| LOH
|
|
| |
in prostate carcinoma | | constitutional
|
|
| --over
|
| |
associated to prolonged survival and increased tube formation when they were stimulated with vascular endothelial growth factor (VEGF) | | tumoral
|
|
| --over
|
| |
on tumors correlates with poor prognosis and high risk of metastasis | | tumoral
|
|
| --over
|
| |
in lung cancer and malignant melanoma | |
| Susceptibility
|
to risk of infection by the receptor-targeting pathogens |
| Variant & Polymorphism
other
| distinct polymorphisms have the potential to decrease or increase the risk of infection by the receptor-targeting pathogens |
| 
|
Candidate gene
| Marker
| melanoma biomarker | |
potential marker of metastatic carcinoma and advanced carcinoma, and may contribute to tumor cell EMT | |
| Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | skin | | |
| in malignant melanoma | | cancer | | | |
| targeting the endothelial up-regulation of CEACAM1 might be promising for antiangiogenic tumor therapy |
| | |
|
| Ceacam1-/- mice exhibit a significant increase in basal vascular permeability related to increased basal Akt and endothelial nitric oxide synthase (eNOS) activation in primary murine lung endothelial cells |